Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Calidi Biotherapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is D. Sanders (Form 8-K filed 2026-06-23). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital, LLC (filed 2026-05-15).
Who is behind it
Calidi Biotherapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- Allan Camaisa: Executive Officer, Director (Form D, 2024-06-06)
- Andrew Jackson: Executive Officer (Form D, 2024-06-06)
- Boris Minev: Executive Officer (Form D, 2024-06-06)
- Wendy Pizarro: Executive Officer (Form D, 2024-06-06)
- Alan R. Stewart: Director (Form D, 2024-06-06)
- Scott Leftwich: Director (Form D, 2024-06-06)
- George Ng: Director (Form D, 2024-06-06)
- James A. Schoeneck: Director (Form D, 2024-06-06)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2026-05-15 | Armistice Capital, LLC | 9.99% |
| Schedule 13D, 2026-03-31 | Gavrilov Ognian Anguelov | 0.3% |
| Schedule 13D, 2026-03-09 | Gavrilov Ognian Anguelov | 9.8% |
| Schedule 13G/A, 2026-02-10 | Lincoln Alternative Strategies LLC | 0% |
| Schedule 13G, 2026-02-04 | Gavrilov Ognian Anguelov | 7.8% |
| Schedule 13G, 2025-08-27 | Lincoln Alternative Strategies LLC | 14.46% |
| Schedule 13G/A, 2025-08-14 | Armistice Capital, LLC | 4.99% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-23 | D. Sanders | appointed |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-06-06 | $5.55M | $5.55M |
| Form D, 2024-03-21 | $3.50M | $3.50M |
| Form D, 2024-03-21 | $1M | $1M |
| Form D, 2024-03-21 | $10K | $10K |
| Form D, 2024-03-21 | $195K | $341K |
| Form D, 2024-03-21 | $33K | $65K |
Latest IPO step: Calidi Biotherapeutics, Inc. filed its final IPO prospectus, ticker CLDI (424B4, 2025-08-21).
IPO filings: 424B4, 2025-08-21, S-1, 2025-08-15, S-1, 2025-07-03, S-1, 2024-12-12; ticker CLDI on NYSE American.
Acquisitions reported on Form 8-K, Item 2.01: acquired Materials in Schedule 1 (2025-10-31).
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/calidi-biotherapeutics